Navigation Links
Dyadic International Strengthens Management Team

JUPITER, Fla., May 4 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology company, is pleased to announce the following management changes in support of its long-term growth objectives:

(Logo: )

The appointment of Anne E. Whitehead as Executive Director of Strategic Alliances. Ms. Whitehead brings to Dyadic a high level of legal, financial and strategic expertise coupled with an extensive network of contacts from her 20 years of active participation in the New York business and legal communities. At Dyadic, she will be responsible for identifying, cultivating and securing strategic alliances and collaborations. Ms. Whitehead began her career at the law firm, Shearman & Sterling LLP, where she specialized in international law representing major multi-national clients in a wide range of transactions. She later worked for five years with the law firm, Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and corporate governance matters. Prior to joining Dyadic, Ms. Whitehead provided consulting services to clients on international strategic matters and project finance transactions.

Ms. Whitehead is a member of the Board of Overseers of The International Rescue Committee, a humanitarian organization which assists refugees worldwide, and has served as its General Counsel. She has also served as a Term Member of The Council on Foreign Relations and as a member of the Advisory Board of the Freeman Spogli Institute for International Studies at Stanford University. As a Trustee of The Whitehead Foundation, Ms. Whitehead has been involved in a wide range of domestic and international charitable activities. Ms. Whitehead holds a B.A. degree in political science from Stanford University and a law degree from The George Washington University.

The appointment of Thomas M. O'Shaughnessy as Vice President Sales & Marketing. Mr. O'Shaughnessy brings to Dyadic over 20 years of sales, marketing and business development experience in the chemical industry. In his new role, he will be responsible for all of Dyadic's global sales, marketing and business development activities for its industrial enzyme business. Mr. O'Shaughnessy began his career with the General Electric Company where he spent 12 years in various sales and marketing positions of increasing responsibility and leadership. He later worked for six years at Occidental Chemical Corporation, the sixth largest chemical operation in the United States. For the past eight years prior to joining Dyadic, Mr. O'Shaughnessy has served as the Global Business Manager for Hexion Specialty Chemicals, Inc. (formerly Borden Chemical), the world's largest producer of thermosetting resins, performance adhesives, UV-curable coatings and the building-block chemical formaldehyde for various wood and industrial markets. Mr. O'Shaughnessy is Six Sigma certified and earned a B.S. degree in computer sciences with a minor in marketing from Plattsburgh State University.

The promotion of Richard H. Jundzil to Vice President of Operations. Mr. Jundzil has served as Dyadic's Director of Development & Quality since September 2008 and has held various laboratory, quality and regulatory positions of increasing responsibility since joining Dyadic in August 2003. In his new role, Mr. Jundzil will continue to manage the production and distribution of Dyadic's enzyme products as well as its laboratories in Greensboro, North Carolina and Jupiter, Florida. Mr. Jundzil has 17 years of quality and operations experience in the biotechnology industry. Prior to joining Dyadic, Mr. Jundzil worked for ten years at Genzyme Corporation as both a researcher and process engineer producing enzymes for patients with rare genetic diseases. Mr. Jundzil earned his B.S. degree in biotechnology sciences from Boston University.

The promotion of Brian E. Murdoch to Senior Director Sales & Technical Development. Mr. Murdoch has served as Dyadic's Director of Sales & Marketing since September 2008. Upon joining Dyadic in January 2005, Mr. Murdoch was initially responsible for managing Dyadic's pulp and paper enzymes business and later became responsible for sales, business development and technical support for all of Dyadic's industrial enzyme markets. Prior to joining Dyadic, Mr. Murdoch was a Project Manager with Dutton Engineering, a private design firm in Greenville, South Carolina. Prior to that, Mr. Murdoch worked for five years in technical sales positions at Enzymatic Deinking Technologies (EDT), a private enzyme distributor in Norcross, Georgia. Mr. Murdoch earned his B.S. degree in biochemistry with a minor in chemistry from Clemson University.

Mark Emalfarb, Dyadic's President and Chief Executive Officer, stated, "Dyadic is moving forward. The appointment and promotion of these individuals to complement our existing management team reflects Dyadic's commitment to build and maintain a strong and dynamic leadership structure. These executives are seasoned performers in their respective fields and have all exhibited the level of skill, work ethic and loyalty that Dyadic values in its leaders. Each of them will play a critical role in helping Dyadic maximize the worldwide growth of its industrial enzyme business and the leveraging of its technologies on a global scale through additional licensing transactions and strategic collaborations."

About Dyadic

Dyadic is a leading-edge early-stage biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.  Please visit Dyadic's website at

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Extends Collaboration With The Scripps Research Institute
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
4. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
5. Arrow International Files and Mails Definitive Proxy Materials
6. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
7. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
8. Viragen International to Reverse Split Its Common Stock
9. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
10. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
11. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has ... Prix, to represent the First–Person View (FPV) racing community. , FPV racing has exploded ... of racing and several new model aviation pilots have joined the community because of ...
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... Nov. 24, 2015 Capricor Therapeutics, Inc. ... on the discovery, development and commercialization of first-in-class therapeutics, ... Executive Officer, is scheduled to present at the 2015 ... 10:50 a.m. EST, at The Lotte New York Palace ... . --> ...
Breaking Biology Technology:
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):